Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Float Short %

1.07

Margin Of Safety %

Put/Call OI Ratio

0.88

EPS Next Q Diff

0.92

EPS Last/This Y

EPS This/Next Y

1.57

Price

202.07

Target Price

208.12

Analyst Recom

1.73

Performance Q

21.53

Relative Volume

0.98

Beta

0.62

Ticker: ABBV




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-01-23ABBV170.650.900.50266174
2025-01-24ABBV170.310.880.67272138
2025-01-27ABBV176.910.890.45270324
2025-01-28ABBV174.780.880.25275909
2025-01-29ABBV175.240.870.84281270
2025-01-30ABBV175.620.870.69283605
2025-01-31ABBV183.930.860.43297573
2025-02-03ABBV190.180.870.16287565
2025-02-04ABBV189.930.850.44299086
2025-02-05ABBV191.750.840.42305437
2025-02-06ABBV192.920.870.62314765
2025-02-07ABBV190.620.890.42320812
2025-02-10ABBV190.380.900.54309328
2025-02-11ABBV191.890.890.55310376
2025-02-12ABBV193.050.890.72312074
2025-02-13ABBV193.450.890.44314514
2025-02-14ABBV192.840.870.71324872
2025-02-18ABBV196.270.880.32321626
2025-02-19ABBV197.330.871.31331982
2025-02-20ABBV200.940.870.51334812
2025-02-21ABBV201.20.880.37343833
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-01-23ABBV170.676.718081.010.94
2025-01-24ABBV170.246.717824.510.94
2025-01-27ABBV176.936.718773.810.94
2025-01-28ABBV174.796.717607.510.94
2025-01-29ABBV175.216.717935.010.94
2025-01-30ABBV175.65-15.817933.510.94
2025-01-31ABBV183.80-17.218950.410.94
2025-02-03ABBV190.146.118669.412.10
2025-02-04ABBV189.959.517859.012.25
2025-02-05ABBV191.789.518290.912.26
2025-02-06ABBV192.949.518217.012.26
2025-02-07ABBV190.629.117862.612.24
2025-02-10ABBV190.349.118117.712.26
2025-02-11ABBV191.869.118337.912.26
2025-02-12ABBV193.069.118301.212.26
2025-02-13ABBV193.429.118058.012.26
2025-02-14ABBV192.879.118079.212.26
2025-02-18ABBV196.279.122603.112.26
2025-02-19ABBV197.359.121626.312.26
2025-02-20ABBV200.909.121918.512.26
2025-02-21ABBV202.079.121632.412.26
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-01-23ABBV-4.61-0.060.96
2025-01-24ABBV-4.61-0.060.96
2025-01-27ABBV-4.610.100.96
2025-01-28ABBV-4.610.101.03
2025-01-29ABBV-4.610.101.03
2025-01-30ABBV-4.610.101.03
2025-01-31ABBV-4.610.101.03
2025-02-03ABBV-4.610.021.03
2025-02-04ABBV-4.610.021.03
2025-02-05ABBV-4.610.021.03
2025-02-06ABBV-4.610.021.03
2025-02-07ABBV-4.610.021.03
2025-02-10ABBV-0.13-0.241.03
2025-02-11ABBV-0.02-0.241.03
2025-02-12ABBV-0.02-0.241.08
2025-02-13ABBV-0.11-0.241.07
2025-02-14ABBV-0.11-0.241.07
2025-02-18ABBV-0.110.781.07
2025-02-19ABBV-0.050.781.07
2025-02-20ABBV-0.060.781.07
2025-02-21ABBV-0.060.781.07
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

2.16

Avg. EPS Est. Current Quarter

2.52

Avg. EPS Est. Next Quarter

3.08

Insider Transactions

-0.06

Institutional Transactions

0.78

Beta

0.62

Average Sales Estimate Current Quarter

12925

Average Sales Estimate Next Quarter

14681

Fair Value

201.5

Quality Score

73

Growth Score

83

Sentiment Score

89

Actual DrawDown %

2.5

Max Drawdown 5-Year %

-32.1

Target Price

208.12

P/E

84.5

Forward P/E

14.5

PEG

5.52

P/S

6.33

P/B

107.29

P/Free Cash Flow

20.01

EPS

2.39

Average EPS Est. Cur. Y​

12.26

EPS Next Y. (Est.)

13.84

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

7.52

Relative Volume

0.98

Return on Equity vs Sector %

108.2

Return on Equity vs Industry %

100.5

EPS 1 7Days Diff

EPS 1 30Days Diff

0.08

EBIT Estimation

21632.4
AbbVie Inc.
Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 55000
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta/Venclyxto to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic to treat neurologic diseases; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duopa and Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; and Qulipta for episodic and chronic migraine, as well as other neuroscience products. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
stock quote shares ABBV – AbbVie Inc. Stock Price stock today
news today ABBV – AbbVie Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch ABBV – AbbVie Inc. yahoo finance google finance
stock history ABBV – AbbVie Inc. invest stock market
stock prices ABBV premarket after hours
ticker ABBV fair value insiders trading